Why People With Early Lung Cancer Keep or Stop Taking Osimertinib After Surgery
Interviews patients and doctors about staying on osimertinib treatment for early non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Barriers and Facilitators of Persistence With Adjuvant Osimertinib
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with lung cancer (NSCLC) who took osimertinib after surgery, and for doctors who prescribe it. Participants will be interviewed about why people stay on or stop this treatment.
- Age
- Patients: 18 years or older. Physicians: age not stated.
- Sex
- All sexes can join.
- Disease stage
- Early-stage non-small cell lung cancer (NSCLC).
- Earlier treatment
- Patients must have received osimertinib after surgery (adjuvant treatment), either less than 34 months and then stopped, or at least 34 months (stopped or still taking it). If stopped or finished, this must have happened within 6 months before screening.
Main reasons for not taking part
- Received osimertinib as adjuvant therapy inside an interventional clinical trial
- Received 1st generation EGFR-TKIs as adjuvant therapy
- Signs of memory or thinking problems that would get in the way of an interview
- Does not know or understand their own medical condition
- Physicians who cannot or will not follow study procedures
Read by machine on 12 November 2026.
Where in China
- BeijingHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07542210
- Record updated
- 16 October 2026
- Original description
This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.Read full original descriptionShow less
Cross-sectional Qualitative Study to Identify Barriers and Facilitators of Persistence With 3rd Generation EGFR-TKI Osimertinib as Adjuvant Treatment (SECURE)
This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.
Inclusion: Adults (≥18 years) with NSCLC who have received osimertinib as the 3rd generation EGFR-TKI adjuvant therapy and meet one of the following: Patients who received adjuvant osimertinib for less than 34 months and discontinued treatment (off treatment), or Patients who received adjuvant osimertinib for at least 34 months (either off treatment or still on treatment); For off treatment patients, discontinuation or completion of osimertinib is required to occur within 6 months by screening; Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes; Licensed medical oncologists, thoracic surgeons, or pulmonologists with experience of prescribing osimertinib as adjuvant treatment and actively managing patients who will participate the interview; Managed 5 patients with early-stage NSCLC receiving osimertinib within the past 6 months; Holding a professional title equivalent to or higher than attending physician; Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.
Exclusion: Evidence of cognitive impairment that would likely to interfere with participation in an interview, as informally assessed during screening; Unaware of or do not understand their own medical condition; For physicians; Prior receipt of 3rd generation EGFR-TKI as adjuvant therapy as part of any interventional clinical trial; Prior receipt of 1st generation EGFR-TKIs as adjuvant therapy; Unable or unwilling to follow study procedures.
For patient.